The latest news and updates on Sooma tDCS™, neurostimulation treatment, and what’s happening at Sooma Medical.

Sooma closes 2025 with major milestones in improved access to better depression and pain care globally

Read more

FDA approved tDCS for at-home depression treatment

Read more

Science round-up webinar: tDCS in Depression and Chronic Pain – Clinical Advancements 2025

Read more

Sooma launches direct-to-patient brain stimulation therapy for depression and chronic pain in Finland and Germany

Read more

Sooma Announces Medical Technology Expert Andreas Hartlep as New CEO

Read more
TGA Approves Sooma's latest at-home tDCS device

TGA approves Sooma’s at-home brain stimulation for depression in Australia

Read more

Sooma Medical Announces Pivotal FDA IDE Clinical Trial for At-Home Brain Stimulation Device for Depression Treatment

Read more

Sooma Pioneers the Integration of Brain Stimulation into Primary Care, Improving Access to Early-Stage Depression Treatment

Read more
Clinician instruction patient during first Sooma Treatment

Sooma Partners with JSTT to Introduce Brain Stimulation Treatments in Occupational Healthcare

Read more

Prioritizing Youth Mental Health: A Call to Action

Read more

Sooma Secures €5M Funding for At-home Brain Stimulation Therapies

Read more

Dr. Daniel Blumberger Joins Sooma’s Science Advisory Board 

Read more